Motif Neurotech Receives FDA Approval to Begin First Clinical Trial of its Therapeutic BCI for Treatment-Resistant Depression
The RESONATE early feasibility study will assess safety and viability of the wirelessly-powered XCS System in patients with treatment-resistant depression across eight leading medical institutions. HOUSTON–(BUSINESS WIRE)–Motif Neurotech, a brain-computer interface (BCI) company developing technologies for mental health, today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) … [Read more…]
